GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yichang HEC ChangJiang Pharmaceutical Co Ltd (HKSE:01558) » Definitions » Asset Turnover

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Asset Turnover : 0.24 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Yichang HEC ChangJiang Pharmaceutical Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Yichang HEC ChangJiang Pharmaceutical Co's Revenue for the six months ended in Dec. 2023 was HK$3,375 Mil. Yichang HEC ChangJiang Pharmaceutical Co's Total Assets for the quarter that ended in Dec. 2023 was HK$14,322 Mil. Therefore, Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover for the quarter that ended in Dec. 2023 was 0.24.

Asset Turnover is linked to ROE % through Du Pont Formula. Yichang HEC ChangJiang Pharmaceutical Co's annualized ROE % for the quarter that ended in Dec. 2023 was 25.94%. It is also linked to ROA % through Du Pont Formula. Yichang HEC ChangJiang Pharmaceutical Co's annualized ROA % for the quarter that ended in Dec. 2023 was 14.71%.


Yichang HEC ChangJiang Pharmaceutical Co Asset Turnover Historical Data

The historical data trend for Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yichang HEC ChangJiang Pharmaceutical Co Asset Turnover Chart

Yichang HEC ChangJiang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.25 0.09 0.32 0.51

Yichang HEC ChangJiang Pharmaceutical Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.12 0.21 0.25 0.24

Competitive Comparison of Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover falls into.



Yichang HEC ChangJiang Pharmaceutical Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=6884.884/( (13277.515+13939.478)/ 2 )
=6884.884/13608.4965
=0.51

Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=3374.946/( (14705+13939.478)/ 2 )
=3374.946/14322.239
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Yichang HEC ChangJiang Pharmaceutical Co  (HKSE:01558) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Yichang HEC ChangJiang Pharmaceutical Co's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=2106.9/8121.255
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(2106.9 / 6749.892)*(6749.892 / 14322.239)*(14322.239/ 8121.255)
=Net Margin %*Asset Turnover*Equity Multiplier
=31.21 %*0.4713*1.7635
=ROA %*Equity Multiplier
=14.71 %*1.7635
=25.94 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Yichang HEC ChangJiang Pharmaceutical Co's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=2106.9/14322.239
=(Net Income / Revenue)*(Revenue / Total Assets)
=(2106.9 / 6749.892)*(6749.892 / 14322.239)
=Net Margin %*Asset Turnover
=31.21 %*0.4713
=14.71 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Yichang HEC ChangJiang Pharmaceutical Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of Yichang HEC ChangJiang Pharmaceutical Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Business Description

Traded in Other Exchanges
N/A
Address
No. 38 Binjiang Road, Yidu, Hubei Province, Yichang, CHN
Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Olmesartan Tablets, and Clarithromycin Tablets.
Executives
Shao Guan Xin Yu Neng Shi Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Xiang Gang Dong Yang Guang Xiao Shou You Xian Gong Si 2101 Beneficial owner
Shen Zhen Shi Dong Yang Guang Shi Ye Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Guang Dong Dong Yang Guang Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Ru Yuan Yao Zu Zi Zhi Xian Xin Jing Ke Ji Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Ru Yuan Yao Zu Zi Zhi Xian Yu Neng Dian Zi Shi Ye You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Meilan 2201 Interest of corporation controlled by you
Hua Xiaoyi 2201 Interest of corporation controlled by you
Zhang Yushuai 2201 Interest of corporation controlled by you
Blackstone Dawn Pte. Ltd. 2101 Beneficial owner
Blackstone Tactical Opportunities Management Associates (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Inc. 2201 Interest of corporation controlled by you
Btof (dawn Feeder) (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Management Associates Iii (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Lr Associates (cayman) – Nq Ltd. 2201 Interest of corporation controlled by you

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Headlines

No Headlines